Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HS235 Added to Background Treatment in Adults With PAH

NCT07143448 is registered in ClinicalTrials.gov with 35Pharma Inc as lead sponsor.

NCT NCT07143448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07143448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HS235 Added to Background Treatment in Adults With PAH
Lead sponsor
35Pharma Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 19, 2026
Completion date
November 30, 2028
Enrollment
90 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension